CryoPort screens as a peer-leading margin and growth story, but heavy insider selling, a failed asymmetry gate, and a stale analyst target leave the engine cautious despite a comfortable balance sheet and a positive earnings-surprise track record.
Thesis pillars
- Industry Growth Leader Margins↓Deteriorating
- Material Insider Selling Heavy Gate→Stable
- Negative Asymmetry Limited Upside→Stable
- +2 more pillars — see the Why tab for full reasoning
CryoPort, Inc. (CYRX) Stock Analysis
Industrials · Integrated Freight & Logistics
Hold if already holding. Not a fresh buy at $15.48, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: Americas (74.5%); Concentration risk — Supplier: sole sourced component manufacturers.
Cryoport provides integrated temperature-controlled supply chain solutions -- BioLogistics, BioStorage, BioServices, cryopreservation, and cryogenic equipment manufacturing via MVE Biological Solutions -- supporting cell and gene therapy, biopharmaceutical, and broader life... Read more
Hold if already holding. Not a fresh buy at $15.48, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: Americas (74.5%); Concentration risk — Supplier: sole sourced component manufacturers. Chart setup: No clear chart pattern; technical signals are mixed. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.5/10, moderate confidence.
Passes 5/9 gates (positive momentum, no SEC red flags, news boost analyst 0.60, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity. Suitability: aggressive.
About CryoPort, Inc.
About CryoPort, Inc.
Cryoport delivered $176.2 million in total revenue for 2025, up 12.4% year over year, split 54.8% from its Life Sciences Services segment (BioLogistics, BioStorage, BioServices, and cryopreservation) and 45.2% from its Life Sciences Products segment, centered on MVE Biological Solutions' cryogenic freezer and dewar manufacturing. The Americas generated 74.5% of 2025 revenue by origin, with EMEA contributing 14.3% and Asia-Pacific 11.2%. The company supported 760 clinical trials and 20 commercially approved cell and gene therapies as of December 31, 2025.
Cryoport earns revenue primarily from temperature-controlled logistics, biostorage, and cryopreservation services billed to biopharmaceutical companies, contract research and manufacturing organizations, central laboratories, fertility clinics, and academic institutions, supplemented by cryogenic freezer and dewar sales through MVE. One customer within the Life Sciences Services segment accounted for 10.2% of total revenue in 2025, versus no single customer above 10% in 2024 or 2023, reflecting growing reliance on large accounts as cell and gene therapy programs commercialize. MVE manufactures in the United States and China, while Cryoport depends on third-party manufacturers, some sole-sourced, for component parts used across its shipping and monitoring systems. During the second quarter of fiscal 2025, the company divested its CRYOPDP specialty courier business to DHL for $133.0 million plus repayment of roughly $77.2 million in intercompany loans, redirecting the business toward EMEA and APAC expansion through a new DHL partnership.
Show full overview
Cryoport's supply chain carries a single-source dependency: the 10-K discloses that the company acquires component parts from various independent manufacturers, some of which are sole sourced, and that a labor strike, natural disaster, or other disruption affecting one of these suppliers could cause significant delays or a cessation in producing components used in its temperature-controlled shipping systems. Because Cryoport's Chain of Compliance model depends on maintaining continuous custody and condition control for irreplaceable cell and gene therapy materials, a prolonged component shortage would directly threaten its ability to serve the 760 clinical trials and 20 commercial therapies it currently supports.
See also: Industrials · Integrated Freight & Logistics
From CryoPort, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-24Recent Developments — CryoPort, Inc.
Latest news
- NEWS BTIG Maintains Buy on CryoPort, Raises Price Target to $25 — benzinga Jul 24, 2026 positive
Generated 2026-07-25T09:22:35Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWCustomerone customer (Life Sciences Services segment)10%10-K Item 1: 'During the year ended December 31, 2025, one customer in our Life Sciences Services reportable segment accounted for 10.2% of our total revenue.'
- HIGHGeographicAmericas75%10-K Item 1: 'Americas ... 74.5'
- HIGHSuppliersole sourced component manufacturers10-K Item 1A: 'We currently acquire various component parts for our solutions from various independent manufacturers, some of which are sole sourced.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $15.48, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: Americas (74.5%); Concentration risk — Supplier: sole sourced component manufacturers. Chart setup: No clear chart pattern; technical signals are mixed. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $16.55 (+6.9%), stop $14.41 (−7.4%), A.R:R -0.9:1. Score 5.5/10, moderate confidence.
Take-profit target: $16.55 (-9.2% upside). Target $16.55 (+6.9%), stop $14.41 (−7.4%), A.R:R -0.9:1. Stop-loss: $14.41.
Concentration risk — Geographic: Americas (74.5%); Concentration risk — Supplier: sole sourced component manufacturers; Analyst target reached - limited upside remaining.
CryoPort, Inc. trades at a P/E of N/A (forward -25.9). TrendMatrix value score: 5.3/10. Verdict: Hold.
16 analysts cover CYRX with a consensus score of 4.3/5. Average price target: $16.
What does CryoPort, Inc. do?Cryoport provides integrated temperature-controlled supply chain solutions -- BioLogistics, BioStorage, BioServices,...
Cryoport provides integrated temperature-controlled supply chain solutions -- BioLogistics, BioStorage, BioServices, cryopreservation, and cryogenic equipment manufacturing via MVE Biological Solutions -- supporting cell and gene therapy, biopharmaceutical, and broader life sciences customers worldwide. The company generated $176.2 million in revenue in 2025, up 12.4% year over year, with 74.5% originating in the Americas and one customer accounting for 10.2% of total revenue.